# Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

> **NCT05185089** · PHASE2 · COMPLETED · sponsor: **Nerre Therapeutics Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Cough
- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Orvepitant Maleate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05185089
- **Lead sponsor:** Nerre Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-06-19
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185089, "Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05185089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*